The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.

This is a randomized, open-label, multi-center, Phase 4 study to assess the changes in liver enzymes related to treatment with buprenorphine/naloxone (BUP/NX) and methadone (MET) in participants entering opioid agonist treatment. Randomization will be stratified, within site, according to normal versus abnormal screening liver function tests. Participants meeting entry criteria will be dosed for 24 weeks during the active phase of the study with assessment of liver function at weeks 1, 2, 4, 8, 12, 16, 20, 24 and with follow-up assessments at week 32. Clinicians will be encouraged to treat with adequate doses of BUP/NX and MET.

Inclusion Criteria:

1. Were age 18 years or older,

2. Met DSM-IV-TR criteria for opioid dependence,

3. Were in good general health, or, in case of a medical/psychiatric condition requiring ongoing treatment, were under the care of a physician willing to continue participant's medical management and cooperate with study physicians,

4. For female participants, use of one of the following acceptable methods of birth control:

   1. oral contraceptives
   2. barrier (diaphragm or condom) with spermicide
   3. IUD
   4. intrauterine progesterone contraceptive system
   5. levonorgestrel implant
   6. medroxyprogesterone acetate contraceptive injection
   7. contraceptive transdermal patch
   8. hormonal vaginal contraceptive ring
   9. surgical sterilization
   10. complete abstinence from sexual intercourse

5. Able to read and verbalize understanding of the study and voluntarily sign study informed consent form.

Exclusion Criteria:

1. ALT or AST values > 5 times the upper limit of normal as per testing laboratory range criteria,

2. ALP values >3 times the upper limit of normal per testing laboratory criteria,

3. Any documented past or present history of ascites, presence of esophageal or gastric varices, hepatic encephalopathy or other signs of significant liver disease as indicated by a Model for Endstage Liver Disease score (Kamath et al., 2001) of ≥11,

4. Total bilirubin > 2.0 mg/dl (participants with documented Gilbert's syndrome were not excluded based on this criterion),

5. Prothrombin time more than 3 seconds prolonged,

6. Albumin level less than 2.5 g/dl,

7. Any cardiopathy or risk factor listed below without evidence of a normal ECG* with report performed within 6 months prior to first study medication dose,

   1. Congestive heart failure
   2. Left ventricular hypertrophy
   3. Bradycardia
   4. Hereditary QT prolongation
   5. Uncorrected electrolyte imbalance
   6. Concomitant medications that are known to have a risk of QT interval prolongation; refer to Appendix D for a list of medications.

   Note: The list was not all-inclusive.

   *An ECG was abnormal if one or more of the following occurred:

   Significant ST segment abnormalities:

   • ST segment elevations in two or more continuous leads of > 0.1 mV
   • ST segment depression of greater than 1 mm that are flat or down-sloping at 80 msec after the J point ST segment abnormalities identified as "non-specific" are acceptable. If a potential participant's ECG indicated ST segment elevations or depression consistent with ischemia, the physician obtained a medical history of cardiac symptoms and referred the participant for evaluation.

   Conduction abnormalities:

   • Mobitz II 2nd degree or 3rd degree heart block
   • Atrial fibrillation, atrial flutter, or any non-sinus tachyarrhythmia
   • Three or more consecutive ectopic ventricular complexes at a rate of > 100 per minute.
   • QTc greater than 450 msec in men and 480 msec in women

   Repolarization abnormalities:

   • Acute medical condition that would make participation, in the opinion of the study physician, medically hazardous (e.g., unstable pancreatic, cardiovascular or renal disease, significant anemia)

8. Known allergy or sensitivity to BUP, naloxone or MET or to any of the inactive ingredients in the study medications (including lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate, FD&C Yellow No.6 color, magnesium stearate, Acesulfame K sweetener)

9. Known diagnosis of acute psychosis, severe depression or imminent suicide risk as determined via clinical interview by study physician or surrogates

10. DSM-IV diagnosis of dependence on alcohol requiring immediate medical attention.

11. DSM-IV diagnosis of dependence on benzodiazepines requiring immediate medical attention

12. DSM-IV diagnosis of dependence on other depressants, or stimulants requiring immediate medical attention

13. Participation in an investigational drug study within the past 30 days

14. Treatment with MET, BUP/NX, or BUP for more than 15 of the past 30 days (illicit use of these medications is allowed)

15. Pending legal action that could prohibit study participation

16. Unable or unwilling to comply with study requirements

17. Unable or unwilling to remain in the local area for duration of treatment

18. Poor venous access such that venipuncture could not be accomplished from a vein in an extremity during eligibility

19. Pregnant or lactating (females only)

Adverse events (medical and/or psychiatric) assessment will initiate with participant randomization and will continue through 30 days post last dose of study medication administered. Study staff should contact each participant 30 days after study completion and/or discontinuation of study medication to follow-up on any adverse events continuing at study end and to determine whether the participant experienced any adverse events within the 30 days after discontinuing study medication.

All AEs reported during the course of the study requiring medical attention will be reported to a study physician immediately. A study physician may then meet any participants for whom additional follow-up or AE assessment is indicated. The type of AE, severity of the AE and the relationship of the AE to the study treatments will be assessed by appropriately trained medical personnel and recorded on an AE CRF, according to the procedures described in Section 14.2.